Clarivate Expands Agentic AI Across Cortellis to Streamline Drug Development
Event summary
- Clarivate announced on August 6, 2026, the expansion of agentic AI capabilities across its Cortellis portfolio.
- The new features aim to accelerate drug discovery, enhance safety assessments, and improve competitive strategy workflows.
- Cortellis Drug Discovery Intelligence now allows natural language interaction with complex drug data.
- OFF-X introduces multi-agent intelligence for proactive risk evaluation in drug development.
The big picture
Clarivate's move reflects a broader industry trend toward embedding AI directly into R&D workflows to enhance efficiency. The expansion of agentic AI across Cortellis positions the company as a key player in transforming how life sciences organizations handle complex data and decision-making processes.
What we're watching
- AI Integration
- How quickly life sciences firms adopt these AI-driven workflows to reduce manual effort and accelerate decision-making.
- Competitive Advantage
- Whether Clarivate's agentic AI capabilities will differentiate it from competitors in the drug development intelligence space.
- Regulatory Compliance
- The impact of AI-driven safety assessments on regulatory approval processes and compliance standards.
Related topics